Amgen Novartis amend Aimovig licensing and collaboration agreement
Amgen and Novartis have added an amendment to a licensing and collaboration agreement for the migraine BeiGene reports findings from phase 3 trial of tislelizumab in gastric cancer (updated) The amendments results in Novartis having sole rights to commercialize Aimovig outside of the United States and Japan. Also, Amgen no longer has to pay royalties to Novartis on sales of Aimovig in the U.S. Also, the two companies will no longer share the commercialization costs of Aimovig in the U.S., though they will share development expenses worldwide
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
